AlzeCure’s Alzheimer project has initiated the next clinical phase I study with ACD856
Stockholm, Sweden, October 4, 2021. AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the first participant has been dosed in the company’s next clinical phase I study (multiple ascending dose, MAD) with the candidate drug ACD856, focused on Alzheimer's disease.”It is satisfying that the clinical development program is proceeding according to plan and that we have now begun this follow-up phase I